Vistagen announces new patents for investigational pherine nasal spray to treat migraine
Click Here to Manage Email Alerts
A clinical-stage neuroscience-focused biopharmaceutical company has received new international patents related to an investigational neuroactive pherine nasal spray to potentially treat individuals with migraine.
According to a press release from Vistagen, the patents, which were awarded in Australia, Hong Kong, Japan and Mexico, are expected to be in effect until 2040, and are subject to patent term extensions on a country-by-country basis.
“We are pleased with the expansion of the patent portfolio for PH80 for the treatment of migraine,” Vistagen CEO Shawn Singh told Healio in an email. “The totality of the PH80 intellectual property portfolio enhances our enthusiasm around the potential of PH80 and its novel mechanism of action.”
PH80 is a non-systemic, hormone-free spray formulation developed as a rapid-onset treatment for vasomotor symptoms due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea and migraine. PH80’s mechanism of action does not require systemic absorption or direct activity on neurons in the brain, per the release.